MicroRNA-153 expression and prognosis in non-small cell lung cancer.
BACKGROUND
miR-153 has been found to be significantly decreased in non-small cell lung cancer (NSCLC) tissues; however, its clinical significance has not been investigated.


METHODS
The expression patterns of miR-153 in 137 pairs of human lung cancer tissues and adjacent normal lung tissues were analyzed using qRT-PCR. The relationships between miR-153 expression and clinicopathological parameters were examined by chi-square test. Kaplan-Meier method and the log-rank test were used to determine the difference in overall survival (OS) rates between two groups.


RESULTS
The expression of miR-153 was reduced significantly, compared with adjacent normal lung tissues (P<0.05). We observed that the expression level of miR-153 was positively correlated with the clinical stage (P=0.005), lymph node status (P=0.014), distant metastasis (P=0.004), and differentiated degree (P<0.001) in NSCLC patients. According to the Kaplan-Meier survival analysis, the patients with low miR-153 expression exhibited evidently poorer overall survival rates than those with high miR-153 expression (P=0.003). Multivariate analysis showed that the expression of miR-153 was an independent and significant factor associated with poor OS rates (P=0.002).


CONCLUSIONS
Decreased expression of miR-153 might be a potential unfavorable prognostic factor for patients with NSCLC, and further studies would be needed to prove our findings.
Shandong University Jinan 250100, Shandong, China ; Department of Medical Oncology, Yantaishan Hospital Yantai 264000, Shandong, China.
Wei-Jun
WJ
Chen
Department of Medical Oncology, Yantaishan Hospital Yantai 264000, Shandong, China.
En-Ning
EN
Zhang
Department of Medical Oncology, Yantaishan Hospital Yantai 264000, Shandong, China.
Zhao-Kun
ZK
Zhong
Department of Radiotherapy, Yantaishan Hospital Yantai 264000, Shandong, China.
Mao-Zhu
MZ
Jiang
Department of Medical Oncology, Yantaishan Hospital Yantai 264000, Shandong, China.
Xi-Feng
XF
Yang
Department of Medical Oncology, Yantaishan Hospital Yantai 264000, Shandong, China.
Dong-Mei
DM
Zhou
Department of Chemotherapy, Qilu Hospital, Shandong University Jinan 250117, Shandong, China.
Xiu-Wen
XW
Wang
D014408:Biomarkers, Tumor / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality / Q000556:secondary / Q000628:therapy; D002454:Cell Differentiation; D016009:Chi-Square Distribution; D015536:Down-Regulation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008207:Lymphatic Metastasis; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D060888:Real-Time Polymerase Chain Reaction; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
D014408:Biomarkers, Tumor; C556500:MIRN153 microRNA, human; D035683:MicroRNAs
NSCLC; biomarker; miR-153; microRNA; prognosis